Format

Send to

Choose Destination
See comment in PubMed Commons below
Allergy. 2010 Jan;65(1):56-60. doi: 10.1111/j.1398-9995.2009.02144.x. Epub 2009 Oct 1.

After 6 years with Xolair; a 3-year withdrawal follow-up.

Author information

1
Department of Medicine, Clinical Immunology and Allergy Unit, Karolinska Institute, Stockholm, Sweden.

Abstract

BACKGROUND:

This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma.

METHODS:

The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV(1) and a questionnaire.

RESULTS:

Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P < 0.02) than untreated patients with allergic asthma and lower than expected from their serum IgE antibody levels.

CONCLUSION:

Most of the patients in this study had, still 3 years after closing of 6 years Xolair treatment, a surprisingly mild and stable asthma. Interestingly, the observed, considerable, downregulation of basophil allergen sensitivity, CD-sens, most likely representing mast cell allergen sensitivity, contributed to the clinical results.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center